Omeros | OMER - Net Income


Omeros reported $-32.23M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Adma Biologics USD 45.33M 4.05M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Cytokinetics USD -198.76M 7.27M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
MacroGenics USD -36.77M 22.62M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 4.65M 1.74M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
United Therapeutics USD 333M 58.1M Jun/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026